Education
About Us
Working with TipRanks
Follow Us
23Andme Holding Co (ME)
:ME
ME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $12.76
Previous CloseN/A
Volume74.49K
Average Volume (3M)7.77M
Market Cap
$16.27M
Enterprise Value$65.16M
Total Cash (Recent Filing)$79.35M
Total Debt (Recent Filing)$60.54M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.72
Shares Outstanding19,721,802
10 Day Avg. Volume22,381,633
30 Day Avg. Volume7,771,798
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.48
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap4.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Ownership Overview
47.58% Insiders
12.85% Mutual Funds
5.18% Other Institutional Investors
30.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
The estimated number of people who visited one or more of the websites owned by 23andMe Holding
Desktop Users
Mobile Users
ME FAQ
What was 23Andme Holding Co’s price range in the past 12 months?
23Andme Holding Co lowest stock price was $0.53 and its highest was $12.76 in the past 12 months.
What is 23Andme Holding Co’s market cap?
23Andme Holding Co’s market cap is $16.27M.
When is 23Andme Holding Co’s upcoming earnings report date?
23Andme Holding Co’s upcoming earnings report date is May 22, 2025 which is in 52 days.
How were 23Andme Holding Co’s earnings last quarter?
23Andme Holding Co released its earnings results on Jan 28, 2025. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.02.
Is 23Andme Holding Co overvalued?
According to Wall Street analysts 23Andme Holding Co’s price is currently Overvalued.
Does 23Andme Holding Co pay dividends?
23Andme Holding Co does not currently pay dividends.
What is 23Andme Holding Co’s EPS estimate?
23Andme Holding Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 23Andme Holding Co have?
23Andme Holding Co has 19,721,802 shares outstanding.
What happened to 23Andme Holding Co’s price movement after its last earnings report?
23Andme Holding Co reported an EPS of -$1.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.882%.
Which hedge fund is a major shareholder of 23Andme Holding Co?
Currently, no hedge funds are holding shares in ME
---
23andMe Holding Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ME Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.30%
12-Months-Change
Fundamentals
Return on Equity
-168.95%
Trailing 12-Months
Asset Growth
-54.39%
Trailing 12-Months
Company Description
23Andme Holding Co
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
---
ME Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative developments. While there were significant achievements in board reconstitution, subscription service growth, and improved financial metrics, the company faced challenges with revenue decline, discontinuation of therapeutic programs, and financial liquidity concerns.Read More>---
ME Revenue Breakdown
100.00% Consumer & Research Services
0.00% Therapeutics
---
ME Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ME
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-79.85%
reiterated a buy rating 8 months ago
Copying Steven Mah's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.85% per trade.
---